Qurient

Innovation for
Unmet
Medical
Needs

Global Leader
of Network
R&D

Clinical & non-clinical
pipeline with
Global
standard

Notice

2026-07-29	“ADC 병용 효능 검증 시작”…큐리언트 모카시클립, 트로델비 병용 임상 개시
2026-07-27	큐리언트, ESMO 2026서 모카시클립 임상 1상 완료 결과 공개: 병용 임상 2상의 전략적 근거 제시
2026-07-23	큐리언트, AACR D3에서 이중 페이로드 ADC QP101 비임상 데이터 공개
2026-06-30	콜로라도 의대 연구팀, 큐리언트 모카시클립으로 소아 뇌종양 치료 가능성 확인…"새로운 치료 옵션 기대"
2026-06-29	큐리언트, 대한암학회서 모카시클립의 유방암 ‘백본 테라피’ 가능성 제시

Company

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More
Business philosophy

Innovation for unmet medical needs

Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More
Pipeline

Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More
IR/PR

Dear Qurient shareholders

Qurient would like to share brief updates on current progress made on its portfolio programs. See More